Saturday 17 October 2026
Export XRTX’s income statement to Excel — free account
XORTX Therapeutics Inc.
XRTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 10.5% and free cash flow fell 318.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.24
0.18
−12.68%
Follow XRTX
XORTX Therapeutics Inc. (XRTX) P/E ratio
XORTX Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SLXN Silexion Therapeutics Corp compare | n/m |
| XRTX XORTX Therapeutics Inc. | n/m |
| GOVX GeoVax Labs Inc. compare | n/m |
| HCWB HCW Biologics Inc. compare | n/m |
| NTBLQ Notable Labs, Ltd. compare | n/m |
| ELAB PMGC Holdings Inc. compare | n/m |
| EIGRQ Eiger BioPharmaceuticals, Inc. compare | n/m |
| AFMDQ Affimed N.V. compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)